AstraZeneca PLC - Cambridge, England-based drugmaker - Says Lynparza treatment has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, who have already been treated with chemotherapy either before or after surgery.
The approval, by the US Food & Drug Administration, was based on results from the Olympia phase three trial presented during the 2021 American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine. Notes Lynparza demonstrated a statistically significant and clinical improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, second cancers or death, by 42% versus placebo.
Current stock price: 9,265.00 pence
12-month change: up 33%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
